US Patent

US7417042 — Compounds for enzyme inhibition

Composition of Matter · Assigned to Proteolix Inc · Expires 2026-07-20 · 0y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects peptide-based compounds that inhibit specific activities of certain enzymes, including the chymotrypsin-like activity of the 20S proteasome.

USPTO Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Drugs covered by this patent

Patent Metadata

Patent number
US7417042
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-07-20
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Proteolix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.